Skip to main content

New Releases: Mar 25, 2009

Premium

Molecular diagnostics developer DxS announced the availability of its TheraScreen KRAS Mutation Kit after receiving clearance from the European Union to sell the product in the region.

DxS' TheraScreen KRAS Mutation Kit runs on Roche's LightCycler 480 Instrument II. The test kit is used by doctors to monitor patient response to two colorectal drugs, Amgen's panitumumab (Vectibix) and Merck's cetuximab (Erbitux).

In addition, DxS annouced it has licensed Roche's LightCycler Adapt Software v1.1 to be used with the TheraScreen test kits, which will allow automated processing of KRAS mutation status tests for colorectal cancer patients.

Manchester, UK-based DxS said that the software will be available for installation in territories where the KRAS Mutation Kit is available for sale through Roche, including Europe, Saudi Arabia, South Africa, and Australia.

Last year DxS and Roche penned a worldwide distribution deal for the TheraScreen KRAS test.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.